A clinical study of CAR-NK for treatment of metastatic solid tumors is conducted by Converd’s subsidiary, Hangzhou Youshan Sictech Ltd.

       This clinical study has started in the in the 3rd hospital of Guangzhou Medical University. It is designed to evaluate safety and efficacy of a novel CAR-NK cell therapy for patients with an advanced cancer. The study is titled: Pilot study of NKG2D-ligand targeted CAR-NK cells in patients with metastatic solid tumours, and it is registered in the ClinicalTrials.gov.：https://clinicaltrials.gov/ct2/show/NCT03415100?term=NCT03415100&rank=1 。

      NK cells are a type of immune cells capable killing tumor cells via natural cytotoxicity. CAR-NK refers to engineering Chimeric Antigen Receptor into NK cells in order to target a tumor-associated antigen. CAR-NK offers a promising adoptive immunotherapy for treating cancers. Converd's trial aims to extend this approach to develop clinically applicable CAR-NK therapy for metastatic cancers.